Richard M. Bergenstal

1 week ago | healio.com | Michael Monostra |Richard Smith |Richard M. Bergenstal

Key takeaways: Adults with type 2 diabetes lowered their HbA1c from 8.18% at baseline to 7% at 26 weeks with insulin icodec plus a CGM. Time in range improved by more than 20 percentage points during the study. Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time in range for adults with type 2 diabetes, researchers reported.

Sep 10, 2024 | healio.com | Michael Monostra |Erik Swain |Carol H. Wysham |Richard M. Bergenstal

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Insulin efsitora alfa conferred noninferior HbA1c reductions vs. insulin degludec in two phase 3 trials.

Jun 2, 2024 | healio.com | Michael Monostra |Richard Smith |Richard M. Bergenstal

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: CGM has changed the way providers assess glycemic control for people with diabetes. Providers and patients will both have a role in using CGM to manage diabetes and make treatment decisions in the future.

Mar 9, 2023 | healio.com | Michael Monostra |Richard Smith |Richard M. Bergenstal

Source/Disclosures Source: Bergenstal R, et al. OP 033. Presented at: International Conference on Advanced Technologies & Treatments for Diabetes; Feb. 22-25, 2023; Berlin (hybrid meeting). Disclosures: The InRange study was funded by Sanofi.